Register Login

KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA)

(10% Negative) KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) Announces Delay in inhibition Trials for recurrent pericarditis Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 28, 2026, 11:32 a.m.

    📋 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) - Clinical Trial Update

    Filing Date: 2026-04-28

    Accepted: 2026-04-28 07:32:20

    Event Type: Clinical Trial Update

    Event Details:

    KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) Announces Clinical Trial Update KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC (KNSA) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: inhibition, expected
    • Diseases/Conditions: recurrent pericarditis
    • Clinical Stage: pivotal trial, Phase 2
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Patient Enrollment, Regulatory Process
    • Collaboration: Kiniksa Pharmaceuticals International
    • Updated Timeline: Q1 2026
      • expected in 2H 2026

    🔬 Clinical Development Pipeline (KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC):

    Product Type Development Stage Therapeutic Area Source
    Rilonacept DRUG Phase PHASE3 Recurrent Pericarditis ClinicalTrials.gov
    KPL-387 Other Phase PHASE2 Recurrent Pericarditis ClinicalTrials.gov
    Placebo Other Phase PHASE2 Pericarditis ClinicalTrials.gov
    KPL-914 DRUG Phase PHASE2 Recurrent Pericarditis ClinicalTrials.gov
    Matching Placebo OTHER Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    KPL-404 DRUG Phase PHASE1 Healthy Volunteers ClinicalTrials.gov
    Placebos DRUG Phase PHASE2 COVID 19 ClinicalTrials.gov
    Mavrilimumab DRUG Phase PHASE2 COVID 19 ClinicalTrials.gov
    KPL-716 DRUG Phase PHASE2 Chronic Idiopathic Urticaria ClinicalTrials.gov
    prednisone DRUG Phase PHASE2 Giant Cell Arteritis ClinicalTrials.gov
    Vixarelimab DRUG Phase PHASE2 Prurigo Nodularis ClinicalTrials.gov
    Abiprubart DRUG Phase PHASE2 Sjögrens Disease ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC
    • Ticker Symbol: KNSA

Search

News categories